Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer

Table 2 Univariate and multivariate analysis of various prognostic factors in GC patients

Variables	Univariate			Multivariate
Variables	HR	95% CI	P value	HR	95% CI	P value
Overall survival (OS)
Gender (male)	0.81	0.45–1.45	0.48	0.41	0.94–2.74	0.01*
Age (> 69 year-old)^a	1.26	0.77–2.06	0.36	1.61	0.21–0.81	0.08
Histological type (Intestinal type)	0.93	0.57–1.51	0.76	0.96	0.57–1.64	0.89
T classification (pT3/4)	3.63	1.92–6.84	0.0001*	2.34	1.2–4.58	0.013*
Vessel involvement (present)	4.12	1.65–10.3	0.002*	5.18	1.33–20.1	0.018*
Lymphatic vessel involvement (present)	2.08	0.65–6.62	0.22	0.14	0.02–0.82	0.029*
Lymph node metastasis (present)	3.86	1.9–7.84	0.0002*	2.86	1.26–6.47	0.012*
Distant metastasis (present)	4.15	2.53–6.81	< 0.0001*	2.56	1.46–4.49	0.001*
AZIN1 RNA hyper-editing^b	1.89	1.15–3.08	0.011*	1.98	1.17–3.35	0.011*
Disease free survival (DFS)
Gender (male)	1.45	0.56–3.75	0.44	0.48	0.15–1.53	0.21
Age (> 69 year-old)^a	1.18	0.61–2.27	0.62	0.96	0.48–1.94	0.92
Histological type (Intestinal type)	1.38	0.72–2.66	0.33	1.31	0.65–2.65	0.45
T classification (pT3/4)	4.38	1.99–9.64	0.0002*	3.17	1.34–7.53	0.009*
Vessel involvement (present)	3.08	1.19–7.96	0.02*	7.2	1.3–39.9	0.024*
Lymphatic vessel involvement (present)	1.8	0.55–5.88	0.33	0.12	0.01–1.06	0.06
Lymph node metastasis (present)	7.21	2.54–20.5	0.0002*	4.76	1.42–15.9	0.011*
AZIN1 RNA hyper-editing^b	5.18	2.63–10.2	< 0.0001*	4.55	2.12–9.78	0.0001*

Variables	Univariate			Multivariate
Variables	OR	95% CI	P value	OR	95% CI	P value
Lymph node metastasis (LNM)
Gender (male)	1.41	0.6–3.3	0.43	1.45	0.55–3.83	0.45
Age (> 69 year-old)^a	1.7	0.82–3.52	0.16	1.57	0.68–3.65	0.29
Histological type (Intestinal type)	1.17	0.57–2.41	0.66	1.3	0.55–3.08	0.55
T classification (pT3/4)	2.98	1.41–6.29	0.004*	2.15	0.9–5.15	0.09
Vessel involvement (present)	6.89	2.83–16.8	< 0.0001*	5.2	1.66–16.3	0.005*
Lymphatic vessel involvement (present)	8.29	2.12–32.5	0.002*	2.31	0.45–11.8	0.31
AZIN1 RNA hyper-editing^b	2.52	1.14–5.56	0.023*	3.03	1.19–7.71	0.02*

HR hazard ratio, OR odds ratio
* P < 0.05
^aThe median age at surgery is 69 years in GC patients
^bCut-off thresholds of AZIN1 RNA editing are determined by ROC analysis with Youden’s index for each outcome in GC patients

ISSN: 1479-5876